- Home
- IPEX vs SPRO Comparison
IPEX vs SPRO Comparison
Compare IPEX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPEX | SPRO |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 135.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | IPEX | SPRO |
|---|---|---|
| Price | $10.40 | $2.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.2K | ★ 357.6K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $41.16 | ★ $17.80 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $10.25 | $0.58 |
| 52 Week High | $10.42 | $3.09 |
Technical Indicators
Market Signals| Indicator | IPEX | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 66.10 |
| Support Level | N/A | $2.15 |
| Resistance Level | N/A | $3.09 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 50.00 | 87.69 |
Price Performance
Historical ComparisonAbout IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.